Ratings by Guggenheim (Seamus Fernandez)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/1/2026 | Septerna Inc | SEPN | Maintain | Buy (N/A) |
|
Details | ||
| 6/25/2026 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 6/23/2026 | Apogee Therapeutics Inc | APGE | Downgrade | Neutral (Buy) |
132.55 (132.91) |
0.27% | Details | |
| 6/22/2026 | Tenax Therapeutics | TENX | Maintain | Buy (N/A) |
|
Details | ||
| 6/11/2026 | Septerna Inc | SEPN | New Coverage | Buy (N/A) |
30.47 (34.00) |
11.59% | Details | |
| 5/25/2026 | Avalyn Pharma | AVLN | New Coverage | Buy (N/A) |
28.41 (29.73) |
4.65% | Details | |
| 5/8/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2026 | Aclaris Therapeutis | ACRS | New Coverage | Buy (N/A) |
4.41 (5.56) |
26.08% | Details | |
| 4/22/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 4/17/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 4/8/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (Buy) |
|
Details | ||
| 3/30/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 3/24/2026 | Apogee Therapeutics Inc | APGE | Maintain | Buy (N/A) |
|
Details | ||
| 3/24/2026 | Generate Biomedicines | GENB | New Coverage | Buy (N/A) |
12.27 (17.41) |
41.89% | Details | |
| 3/19/2026 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2026 | Arcutis Biotherapeutics | AQRT | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Buy (N/A) |
6.23 (7.61) |
22.15% | Details | |
| 1/20/2026 | Structure Therapeutics | GPCR | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 1/16/2026 | MBX Biosciences Inc | MBX | Maintain | Buy (N/A) |
|
Details | ||
| 12/23/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (Buy) |
|
Details | ||
| 12/17/2025 | Tenax Therapeutics | TENX | Maintain | Buy (N/A) |
|
Details | ||
| 12/17/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 12/12/2025 | Bristol-Myers Squibb Co. | BMY | Upgrade | Buy (Neutral) |
51.20 (58.13) |
13.54% | Details | |
| 12/9/2025 | Sanofi | SNY | Downgrade | Neutral (Buy) |
48.44 (43.16) |
-10.9% | Details | |
| 12/3/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 11/25/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (Neutral) |
|
Details | ||
| 11/17/2025 | Cidara Therapeutics | CDTX | Downgrade | Neutral (Buy) |
217.71 (221.38) |
1.69% | Details | |
| 11/10/2025 | MBX Biosciences Inc | MBX | Maintain | Buy (N/A) |
|
Details | ||
| 10/8/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 9/29/2025 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 9/25/2025 | Cidara Therapeutics | CDTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2025 | MBX Biosciences Inc | MBX | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2025 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2025 | Tenax Therapeutics | TENX | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2025 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2025 | Cidara Therapeutics | CDTX | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2025 | Structure Therapeutics | GPCR | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 7/21/2025 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Buy (N/A) |
|
Details | ||
| 7/11/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 7/10/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 7/9/2025 | Cidara Therapeutics | CDTX | Maintain | Buy (N/A) |
|
Details | ||
| 7/2/2025 | Apogee Therapeutics Inc | APGE | Maintain | Buy (Buy) |
|
Details | ||
| 6/24/2025 | Cidara Therapeutics | CDTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/24/2025 | Amylyx Pharmaceuticals inc. | AMLX | New Coverage | Buy (N/A) |
5.02 (18.27) |
263.94% | Details | |
| 6/10/2025 | Metsera Inc | MTSR | Maintain | Buy (N/A) |
|
Details | ||
| 5/23/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 5/16/2025 | Cidara Therapeutics | CDTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2025 | Tenax Therapeutics | TENX | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 5/9/2025 | Cidara Therapeutics | CDTX | Maintain | Buy (N/A) |
|
Details | ||
| 4/14/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2025 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2025 | Metsera Inc | MTSR | New Coverage | Buy (N/A) |
31.65 (70.50) |
122.75% | Details | |
| 1/17/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 12/12/2024 | Apogee Therapeutics Inc | APGE | Maintain | Buy (Buy) |
|
Details | ||
| 11/27/2024 | Apogee Therapeutics Inc | APGE | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2024 | Cidara Therapeutics | CDTX | New Coverage | Buy (N/A) |
13.11 (217.71) |
1560.64% | Details | |
| 10/21/2024 | Rhythm Pharmaceuticals | RYTM | New Coverage | Buy (N/A) |
50.85 (114.17) |
124.52% | Details | |
| 10/14/2024 | Tenax Therapeutics | TENX | New Coverage | Buy (N/A) |
3.37 (15.46) |
358.75% | Details | |
| 10/8/2024 | MBX Biosciences Inc | MBX | New Coverage | Buy (N/A) |
23.75 (57.80) |
143.37% | Details | |
| 9/30/2024 | Apogee Therapeutics Inc | APGE | Maintain | Buy (Buy) |
|
Details | ||
| 8/16/2024 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 8/12/2024 | Revance Therapeutic | RVNC | Downgrade | Neutral (Buy) |
3.53 (3.65) |
3.4% | Details | |
| 8/5/2024 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 7/8/2024 | HilleVax, Inc. | HLVX | Downgrade | Neutral (Buy) |
14.06 (2.09) |
-85.14% | Details | |
| 4/29/2024 | Altimmune | ALT | Downgrade | Neutral (Buy) |
7.26 (3.16) |
-56.47% | Details | |
| 3/4/2024 | GlaxoSmithKline | GSK | Upgrade | Buy (Neutral) |
41.90 (53.66) |
28.07% | Details | |
| 1/29/2024 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 1/2/2024 | Apogee Therapeutics Inc | APGE | Maintain | Buy (N/A) |
|
Details | ||
| 1/2/2024 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 1/2/2024 | Icosavax Inc. | ICVX | Downgrade | Neutral (Buy) |
15.68 (15.31) |
-2.36% | Details | |
| 11/17/2023 | Icosavax Inc. | ICVX | New Coverage | Buy (N/A) |
9.31 (15.31) |
64.45% | Details | |
| 8/11/2023 | CymaBay Therapeutic | CBAY | New Coverage | Buy (N/A) |
12.96 (32.48) |
150.62% | Details | |
| 8/8/2023 | Apogee Therapeutics Inc | APGE | New Coverage | Buy (N/A) |
20.70 (132.91) |
542.08% | Details | |
| 5/16/2023 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2023 | HilleVax, Inc. | HLVX | Maintain | Buy (N/A) |
|
Details | ||
| 3/7/2023 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Buy (N/A) |
18.96 (27.69) |
46.04% | Details | |
| 2/28/2023 | Structure Therapeutics | GPCR | New Coverage | Buy (N/A) |
24.00 (53.45) |
122.71% | Details | |
| 1/11/2023 | Albireo Pharma | ALBO | Downgrade | Neutral (Buy) |
43.85 (44.15) |
0.68% | Details | |
| 12/15/2022 | Vaxcyte | PCVX | New Coverage | Buy (N/A) |
45.72 (58.39) |
27.71% | Details | |
| 11/15/2022 | DICE Therapeutics | DICE | New Coverage | Buy (N/A) |
33.23 (47.55) |
43.09% | Details | |
| 11/10/2022 | Revance Therapeutic | RVNC | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2022 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 11/1/2022 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2022 | Zai Lab | ZLAB | Maintain | Buy (N/A) |
|
Details | ||
| 10/10/2022 | Merck | MRK | Upgrade | Buy (Neutral) |
87.60 (129.56) |
47.9% | Details | |
| 10/10/2022 | Bristol-Myers Squibb Co. | BMY | Downgrade | Neutral (Buy) |
69.70 (51.20) |
-26.54% | Details | |
| 9/21/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2022 | Altimmune | ALT | Maintain | Buy (N/A) |
|
Details | ||
| 9/8/2022 | Albireo Pharma | ALBO | New Coverage | Buy (N/A) |
16.67 (44.15) |
164.85% | Details | |
| 8/15/2022 | Altimmune | ALT | Maintain | Buy (N/A) |
|
Details | ||
| 5/24/2022 | HilleVax, Inc. | HLVX | New Coverage | Buy (N/A) |
9.50 (14.06) |
48% | Details | |
| 12/15/2021 | Adagio | ADGI | Downgrade | Neutral (Buy) |
7.26 (4.64) |
-36.09% | Details | |
| 12/7/2021 | Merck | MRK | Downgrade | Neutral (Buy) |
73.42 (87.60) |
19.31% | Details | |
| 9/21/2021 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 9/20/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 8/31/2021 | Adagio | ADGI | New Coverage | Buy (N/A) |
30.38 (4.64) |
-84.73% | Details | |
| 4/26/2021 | CureVac | CVAC | New Coverage | Neutral (N/A) |
116.37 (4.66) |
-96% | Details | |
| 4/13/2021 | Zai Lab | ZLAB | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2021 | Altimmune | ALT | New Coverage | Buy (N/A) |
21.58 (3.16) |
-85.36% | Details | |
| 2/8/2021 | Viela Bio | VIE | Downgrade | Neutral (Buy) |
52.85 (53.01) |
0.3% | Details | |
| 10/19/2020 | Bristol-Myers Squibb Co. | BMY | Upgrade | Buy (Neutral) |
61.24 (58.13) |
-5.08% | Details | |
| 8/24/2020 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 8/24/2020 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 8/12/2020 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Buy (N/A) |
|
Details | ||
| 6/16/2020 | Eli Lilly | LLY | Upgrade | Buy (Neutral) |
141.52 (1213.91) |
757.77% | Details | |
| 4/15/2020 | Zai Lab | ZLAB | New Coverage | Buy (N/A) |
59.60 (19.12) |
-67.92% | Details | |
| 2/27/2020 | Revance Therapeutic | RVNC | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2020 | Arcutis Biotherapeutics Inc. | ARQT | New Coverage | Buy (N/A) |
27.05 (25.81) |
-4.58% | Details | |
| 2/11/2020 | Viela Bio | VIE | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2020 | Dermira | DERM | Downgrade | Neutral (Buy) |
18.95 (7.09) |
-62.59% | Details | |
| 1/7/2020 | Viela Bio | VIE | Maintain | Buy (N/A) |
|
Details | ||
| 1/6/2020 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2019 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2019 | Viela Bio | VIE | New Coverage | Buy (N/A) |
19.65 (53.01) |
169.77% | Details | |
| 8/7/2019 | Allergen | AGN | Downgrade | Neutral (Buy) |
159.49 (193.02) |
21.02% | Details | |
| 4/11/2019 | Eli Lilly | LLY | Downgrade | Neutral (Buy) |
127.24 (141.52) |
11.22% | Details | |
| 3/21/2019 | Dermira | DERM | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2019 | Allergen | AGN | Maintain | Buy (N/A) |
|
Details | ||
| 1/30/2019 | Allergen | AGN | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2019 | Allergen | AGN | Maintain | Buy (N/A) |
|
Details | ||
| 1/4/2019 | Celgene | CELG | Downgrade | Neutral (Buy) |
66.64 (108.24) |
62.42% | Details | |
| 11/27/2018 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 11/20/2018 | Dermira | DERM | New Coverage | Buy (Neutral) |
9.71 (18.95) |
95.16% | Details | |
| 11/16/2018 | Revance Therapeutic | RVNC | New Coverage | Buy (Neutral) |
20.85 (3.65) |
-82.49% | Details | |
| 10/9/2018 | Allergen | AGN | New Coverage | Buy (Neutral) |
190.17 (159.49) |
-16.13% | Details | |
| 10/9/2018 | Bristol-Myers Squibb Co. | BMY | New Coverage | Neutral (Buy) |
62.41 (58.13) |
-6.86% | Details | |
| 10/9/2018 | Merck | MRK | New Coverage | Buy (N/A) |
71.03 (129.56) |
82.4% | Details | |
| 10/9/2018 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
115.02 (127.24) |
10.62% | Details |
